Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to new results.
Click here for original story, Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis
Source: ScienceDaily